Updated ATAGI advice on COVID-19 Vaccine AstraZeneca in response to Delta outbreaks

AstraZeneca continues to support the medical advice from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Oxford-AstraZeneca COVID-19 vaccine, with the latest update provided in the context of outbreaks of the Delta variant of the COVID-19 virus.

Regulatory authorities around the world have stated that the benefit of using our vaccine significantly outweigh the risks across all adult age groups, and this has been reiterated by ATAGI and the Therapeutic Goods Administration (TGA), particularly in the context of the Delta outbreaks.

Real-world evidence published by Public Health England demonstrates that the Oxford-AstraZeneca vaccine maintains very high levels of protection against the Delta variant. In less than 12 months, more than one billion doses of the Oxford-AstraZeneca COVID-19 vaccine have been released for supply to more than 170 countries. Our vaccine continues to be an important tool in overcoming the COVID-19 global health emergency, underpinned by our commitment to provide broad and equitable access, at no profit during the pandemic.

AU-11254; prepared July 2021